title: Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.
abstract: OBJECTIVE
  The present study was designed to assess the effect of monthly ibandronate on health-related quality of life (HR-QoL) in patients with postmenopausal osteoporosis previously treated with weekly bisphosphonates.
  
  
  METHODS
  HR-QoL was assessed by Euroqol (EQ-5D) and Osteoporosis Targeted Quality of Life (OPTQoL) questionnaires.
  
  
  RESULTS
  The EQ-5D questionnaire showed significant improvement associated with ibandronate treatment, occurring in mobility (p < 0.01), usual activity (p < 0.01), pain/discomfort (p < 0.05), and anxiety/depression (p < 0.05). In addition, ibandronate treatment considerably improved patients' perceived health on a visual analog scale (p < 0.001). For the OPTQoL questionnaire, patients reported less physical difficulty (p < 0.001), fewer adaptations in their lives (p < 0.001), and less fear (p < 0.001) with ibandronate than with weekly bisphosphonates.
  
  
  CONCLUSIONS
  The study demonstrated that patients who were transferred from weekly bisphosphonates to a monthly ibandronate experienced improved HR-QoL.
authors.affiliation: Department of Endocrinology, University Hospital Zagreb, Zagreb, Croatia. dkastelan@inet.hr
authors.forename: Darko
authors.initials: D
authors.lastname: Kastelan
authors.forename: Tonko
authors.initials: T
authors.lastname: Vlak
authors.forename: Petar
authors.initials: P
authors.lastname: Lozo
authors.forename: Marina
authors.initials: M
authors.lastname: Gradiser
authors.forename: Sime
authors.initials: S
authors.lastname: Mijic
authors.forename: Tatjana
authors.initials: T
authors.lastname: Nikolic
authors.forename: Blazenka
authors.initials: B
authors.lastname: Miskic
authors.forename: Dolores
authors.initials: D
authors.lastname: Car
authors.forename: Gordana
authors.initials: G
authors.lastname: Tajsic
authors.forename: Tina
authors.initials: T
authors.lastname: Dusek
authors.forename: Zrinka
authors.initials: Z
authors.lastname: Jajic
authors.forename: Frane
authors.initials: F
authors.lastname: Grubisic
authors.forename: Tamara
authors.initials: T
authors.lastname: Poljicanin
authors.forename: Miro
authors.initials: M
authors.lastname: Bakula
authors.forename: Fedja
authors.initials: F
authors.lastname: Dzubur
authors.forename: Matilda
authors.initials: M
authors.lastname: Strizak-Ujevic
authors.forename: Mira
authors.initials: M
authors.lastname: Kadojic
authors.forename: Maja
authors.initials: M
authors.lastname: Radman
authors.forename: Maja
authors.initials: M
authors.lastname: Vugrinec
authors.forename: Zeljka
authors.initials: Z
authors.lastname: Kuster
authors.forename: Marijeta
authors.initials: M
authors.lastname: Pekez
authors.forename: Endi
authors.initials: E
authors.lastname: Radovic
authors.forename: Ljubica
authors.initials: L
authors.lastname: Labar
authors.forename: Zeljka
authors.initials: Z
authors.lastname: Crncevic-Orlic
authors.forename: Mirko
authors.initials: M
authors.lastname: Korsic
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D004164:Diphosphonates / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000523:psychology*; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid